MOR logo

MorphoSys AG American Depositary Shares

MOR

MOR: MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.

more

Show MOR Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of MOR by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by MOR's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Canine antibody libraries Jul. 18, 2023
  • Patent Title: Clinical assessment of m-protein response in multiple myeloma Apr. 04, 2023
  • Patent Title: Treatment for multiple myeloma (mm) Feb. 28, 2023
  • Patent Title: Antibodies targeting glycoprotein vi Jan. 03, 2023
  • Patent Title: Humanized antibodies for cd3 Oct. 18, 2022
  • Patent Title: Peptide libraries Jun. 07, 2022
  • Patent Title: Anti-cd19 antibody formulations Jun. 07, 2022
  • Patent Title: Fab molecules with a rodent hinge region and a non-rodent ch1 region Feb. 22, 2022
  • Patent Title: Combinations and uses thereof Jan. 18, 2022
  • Patent Title: Polypeptide library Aug. 10, 2021
  • Patent Title: Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 Jul. 13, 2021
  • Patent Title: Nucleic acid encoding anti-gm-csf antibodies Jun. 08, 2021
  • Patent Title: Canine antibody libraries May. 25, 2021
  • Patent Title: Rodent combinatorial antibody libraries Feb. 16, 2021
  • Patent Title: Treatment for rheumatoid arthritis Feb. 09, 2021
  • Patent Title: Peptide libraries Nov. 03, 2020
  • Patent Title: Antagonists of il17c for the treatment of inflammatory disorders Oct. 27, 2020
  • Patent Title: Complex-specific antibodies and antibody fragments and its use Sep. 15, 2020
  • Patent Title: Collection and methods for its use May. 12, 2020
  • Patent Title: Treatment for multiple myeloma (mm) Jan. 14, 2020
  • Patent Title: Methods of treatment using anti-gm-csf antibodies Aug. 13, 2019
  • Patent Title: Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-cd38 antibody in combination with thalidomine, lenalidomids, or pomalidomide Jun. 04, 2019
  • Patent Title: Fusion proteins and uses thereof Apr. 30, 2019
  • Patent Title: Antibodies for il-17c Apr. 16, 2019
  • Patent Title: Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 Jan. 22, 2019
  • Patent Title: Antibodies targeting m-csf Sep. 25, 2018
  • Patent Title: Method for treatment of osteoarthritis with c-fms antagonists Jun. 26, 2018
  • Patent Title: Anti-staphylococcal antibodies Jan. 23, 2018
  • Patent Title: Antibodies targeting m-csf Jan. 02, 2018
  • Patent Title: Method for the treatment of multiple myeloma or non-hodgkins lymphoma with anti-cd38 antibody and bortezomib or carfilzomib Sep. 19, 2017
  • Patent Title: Anti-cd38 human antibodies and uses thereof Sep. 12, 2017
  • Patent Title: Anti-gm-csf antibodies Sep. 05, 2017
  • Patent Title: Use of lysozyme as a tag Jun. 27, 2017
  • Patent Title: Rodent combinatorial antibody libraries May. 16, 2017
  • Patent Title: Collection and methods for its use Apr. 18, 2017
  • Patent Title: Combinations and uses thereof Feb. 28, 2017
  • Patent Title: Collection and methods for its use Jan. 10, 2017
  • Patent Title: Radiolabelled antibody and uses thereof Nov. 08, 2016
  • Patent Title: Combinations and uses thereof Mar. 22, 2016
  • Patent Title: Deconvolution method Feb. 23, 2016
  • Patent Title: Fully human therapeutic antibodies specific for human cd38 Nov. 24, 2015
  • Patent Title: Antibodies for guanylyl cyclase receptors Jul. 28, 2015
  • Patent Title: Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and nhl Nov. 04, 2014
  • Patent Title: Melibiose operon expression system May. 27, 2014
  • Patent Title: Collection and methods for its use May. 20, 2014
  • Patent Title: Collection and methods for its use Apr. 01, 2014
  • Patent Title: Production of oligoclonal mixtures of immunoglobulins in single cells Oct. 08, 2013
  • Patent Title: Protein (poly)peptides libraries Aug. 20, 2013
  • Patent Title: Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38 Jul. 16, 2013
  • Patent Title: Collection and methods for its use Feb. 05, 2013
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of MOR in WallStreetBets Daily Discussion

MOR News

Recent insights relating to MOR

CNBC Recommendations

Recent picks made for MOR stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in MOR

Corporate Flights

Flights by private jets registered to MOR